Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
V InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' Universidad Católica Argentina October 10-11, 2013 Buenos Aires, Argentina FIRST ANNOUNCEMENT The Fifth Conference of IAOC “Current Status and Future of Anti-Cancer Targeted Therapies” will be held in Buenos Aires, Argentina in October 10th and 11th, 2013. An outstanding faculty of speakers from the United States and Europe has committed in this meeting. The conference agenda will focus on new translational advances in the treatment of cancer as well as provide updates of conventional therapies for a number of the most common tumor types. The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development. This meeting is the primary opportunity for oncologists and cancer related health workers to participate in a conference focusing on novel targeted therapies and other treatment advances which are changing the face of cancer care. CO- CHAIRS Román Perez Soler, New York, USA Carlos L. Arteaga, Nashville, USA ORGANIZING COMMITTEE Román Pérez Soler, New York, USA. Carlos L. Arteaga, Nashville, USA. Andrea Blanco, Buenos Aires, Argentina. SCIENTIFIC COMMITTEE Alex Adjei, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, New York, USA Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA Carlos L. Arteaga, M.D., Vanderbilt University School of Medicine, Nashville, USA Hernán Cortes Funes, M.D., Hospital Universitario "12 de Octubre", Madrid, Spain Roman Perez Soler, M.D., Albert Einstein College of Medicine, Bronx, New York, USA Josep Tabernero, M.D., Vall d’Hebron University Hospital, Barcelona, Spain FACULTY (PROVISIONARY) Alex A. Adjei, M.D., Ph.D. Professor and Chair, Department of Medicine Katherine Anne Gioia Chair in Cancer Medicine Roswell Park Cancer Institute Buffalo, New York, USA Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts, USA Carlos L. Arteaga, M.D. Professor of Medicine and Cancer Biology Associate Director for Clinical Research Director, Breast Cancer Program Vanderbilt –Ingram Cancer Center Nashville, Tennessee, USA Joaquim Bellmunt M.D., Ph.D. NAQAA Professor of Medicine Pompeu Fabra University Section Chief, Solid Tumor Oncology (GU & GI) Medical Oncology Service, Hospital del Mar Barcelona, Spain Robert L. Coleman, M.D. Professor & Vice Chair, Clinical Research Department of Gynecologic Oncology & Reproductive Medicine University of Texas, M.D. Anderson Cancer Center Houston, Texas, USA Jorge Cortes, M.D. Professor of Medicine Chief, CML & AML Sections Deputy Chair, Department of Leukemia MD Anderson Cancer Center Houston, Texas, USA Hernán Cortés Funes, M.D. Department of Medical Oncology Hospital Universitario "12 de Octubre" Madrid, Spain John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Chief, Lymphoma Service, Vice Chairman for Clinical Research Weill Cornell Cancer Center New York, New York, USA 2 FACULTY (PROVISIONARY) Román Pérez-Soler, M.D. Chairman, Department of Oncology Montefiore Medical Center Albert Einstein College of Medicine Bronx, New York, USA Daniel P. Petrylak, M.D. Director, Genitourinary Oncology Program Co Director, Signal Transduction Program Yale University Cancer Center New Haven, Connecticut, USA Jeffrey A. Sosman M.D. Professor of Medicine Ingram Professor for Cancer Research Vanderbilt University Medical Center Division of Hematology/Oncology Nashville, Tennessee, USA Josep Tabernero, M.D. Chairman Medical Oncology Department Vall d’Hebron University Hospital Barcelona, Spain Vicente Valero, M.D., F.A.C.P. Professor of Medicine, Deputy Chairman Department of Breast Medical Oncology University of Texas M.D. Anderson Cancer Center Houston, Texas, USA John J. Wright, M.D., Ph.D. Associate Branch Chief Investigational Drug Branch National Cancer Institute Bethesda, Maryland, USA 3 PRELIMINARY PROGRAM NEW ANTICANCER THERAPIES Promising Novel Agents in Early Clinical Trials: Alex A. Adjei, Buffalo, USA New Drug Development at the NCI: John J. Wright, Bethesda, USA Use of Molecular Markers to Select Patients: Román Pérez Soler, New York, USA PI3K/TOR Pathway Inhibitors: Carlos L. Arteaga, Nashville, USA Targeted Therapy for Melanoma: Jeffrey A. Sosman, Nashville, USA WOMEN´S CANCER New Drugs in Breast Cancer: Vicente Valero, Houston, USA Current and Future Treatments in Breast Cancer: Hernán Cortés Fúnes, Madrid, Spain Hormonal Therapies and Combinations to Bypass Resistance: Carlos L. Arteaga, Nashville, USA New Therapies in Ovarian Cancer: Robert L. Coleman, Houston, USA GU AND GI CANCER New Targeted Therapies in Prostate and Renal Cancer: Daniel P. Petrylak, New Haven, USA Advances in the Management of Metastatic Urothelial Cancer: Joaquim Bellmunt, Barcelona, Spain Treatment for Advanced Colorectal Cancer: Josep Tabernero, Barcelona, Spain LUNG CANCER New Targets in Lung Cancer: Alex A. Adjei, New York, USA Advances in Frontline Treatment: Román Pérez Soler, New York, USA 4 PRELIMINARY PROGRAM HEMATOLOGICAL MALIGNANCIES Lymphoma: John P. Leonard, New York, USA Multiple Myeloma: Kenneth C. Anderson, Boston, USA Leukemia: Jorge Cortes, Houston, USA CONFERENCE SECRETARIAT AND INFORMATION E-mail: [email protected] Web: www.oncologyconferences.com.ar 5